Executive Vice President, Drug Development
Dr. Cunniff is responsible for all scientific and regulatory matters associated with new product development, approval and maintenance on a global basis.
Dr. Cunniff joined Marathon from the multinational biopharmaceutical company Lundbeck, Inc. (formerly Ovation Pharmaceuticals), where he served as interim president and vice president for global regulatory affairs, pharmacovigilance and clinical quality assurance. Under his leadership, Lundbeck/Ovation developed and obtained approval for several products to treat CNS disorders and rare diseases. The company also became an industry leader in the creation and implementation of Risk Evaluation and Mitigation Strategies (REMS). Dr. Cunniff also served as the company’s initial corporate compliance officer and led the company’s expansion from North American to global markets.
Dr. Cunniff also worked for Abbott Laboratories, Pfizer/Agouron and Warner-Lambert/Parke Davis where he began his career in 1989. He participated on several successful development and registration programs for anti-infectives, anti-virals and cardiovascular agents.
He serves as clinical instructor of pharmacy for the University of Michigan College of Pharmacy, where he received his doctor of pharmacy degree in 1989.